Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: A LIFE substudy

Michael H. Olsen, Kristian Wachtell, Hans Ibsen, Lars Lindholm, Sverre E. Kjeldsen, Per Omvik, Markku S. Nieminen, Björn Dahlöf, Peter M. Okin, Richard B. Devereux

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstrakt

AIM: To investigate whether in-treatment measurements of subclinical organ damage (SOD) assessed by elevated urine albumin/creatinine ratio (UACR) or electrocardiographic left ventricular hypertrophy improved the prediction of the composite cardiovascular endpoint of cardiovascular death, nonfatal myocardial infarction and stroke beyond in-treatment Framingham risk score (FRS). Methods: Excluding patients with a composite cardiovascular endpoint within the first year of treatment, 598 endpoints occurred in 6460 patients from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study with baseline and 1 year values for UACR, left ventricular hypertrophy by electrocardiography and FRS available. Results: Using Cox-regression analyses, FRS1year [hazard ratio = 1.006 (0.98-1.04)] did not predict the endpoint independently of history of cardiovascular disease [hazard ratio = 1.76 (1.49-2.08)], FRSbaseline [hazard ratio = 1.07 (1.04-1.11)], UACRbaseline [hazard ratio = 1.15 (1.07-1.23), all three P < 0.001], Sokolow-Lyonbaseline [hazard ratio = 1.01 (1.006-1.02), P < 0.01] and treatment allocation, whereas Cornell product1year [hazard ratio = 1.01 (1.006-1.02), P < 0.001] and to some degree UACR1year [hazard ratio = 1.05 (0.99-1.10), P = 0.09] predicted the endpoint independently of history of cardiovascular disease [hazard ratio = 1.71 (1.44-2.02)], FRSbaseline [hazard ratio = 1.08 (1.06-1.10)], Sokolow-Lyonbaseline [hazard ratio = 1.01 (1.007-1.02), both P < 0.001], UACRbaseline [hazard ratio = 1.11 (1.03-1.20), P < 0.01] and treatment allocation decreasing -2 Log likelihood significantly (P < 0.01).Presence of left ventricular hypertrophy by Cornell product1year or UACR1year at least 1 mmol/l [hazard ratio = 1.40 (1.15-1.70), P = 0.001] but not FRS1year above the median baseline value of 20 [hazard ratio = 1.22 (0.94-1.57), not significant] was associated with higher risk of subsequent endpoint after adjustment for history of cardiovascular disease [hazard ratio = 1.82 (1.54-2.15)], FRSbaseline at least 20 [hazard ratio = 1.67 (1.30-2.16)], left ventricular hypertrophy by Sokolow-Lyonbaseline or UACRbaseline at least 1 mmol/l [hazard ratio = 1.61 (1.33-1.94), all P < 0.001] and treatment allocation [hazard ratio = 0.93 (0.79-1.09), not significant]. In contrast to FRS1year at least 20 decreased, SOD1year decreased -2Log likelihood significantly (P < 0.01). Conclusion: Cornell product1year and UACR1year improved in contrast to FRS1year risk prediction based on FRSbaseline, Sokolow-Lyonbaseline and UACRbaseline significantly in LIFE patients during antihypertensive treatment.

OriginalsprogEngelsk
Sider (fra-til)997-1004
Antal sider8
TidsskriftJournal of Hypertension
Vol/bind29
Udgave nummer5
DOI
StatusUdgivet - 1 maj 2011

Fingeraftryk

Udforsk hvilke forskningsemner 'Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: A LIFE substudy' indeholder.

Citationsformater